Literature DB >> 2308145

Inhibition of steroid 5 alpha-reductase by unsaturated 3-carboxysteroids.

D A Holt1, M A Levy, H J Oh, J M Erb, J I Heaslip, M Brandt, H Y Lan-Hargest, B W Metcalf.   

Abstract

A series of unsaturated steroids bearing a 3-carboxy substituent has been prepared and assayed in vitro as inhibitors of human and rat prostatic steroid 5 alpha-reductase (EC 1.3.1.30). It is proposed that the observed tight binding of the 3-androstene-3-carboxylic acids is due to mimicry of a putative, high-energy, enzyme-bound enolate intermediate formed during the NADPH-dependent conjugate reduction of testosterone by steroid 5 alpha-reductase. These compounds were prepared through palladium(0)-catalyzed carbomethoxylations of enol (trifluoromethyl)sulfonates derived from 3-keto precursors. Modification of A and B ring unsaturation and substitution at C-3, -4, -6, and -11 was explored. Mono- and dialkylcarboxamides were employed as 17 beta side chains to enhance inhibitory activity with the human enzyme.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2308145     DOI: 10.1021/jm00165a010

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  3 in total

1.  Identification and selective inhibition of an isozyme of steroid 5 alpha-reductase in human scalp.

Authors:  G Harris; B Azzolina; W Baginsky; G Cimis; G H Rasmusson; R L Tolman; C R Raetz; K Ellsworth
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-15       Impact factor: 11.205

2.  Synthesis and 5α-reductase inhibitory activity of C₂₁ steroids having 1,4-diene or 4,6-diene 20-ones and 4-azasteroid 20-oximes.

Authors:  Sujeong Kim; Yong-ung Kim; Eunsook Ma
Journal:  Molecules       Date:  2011-12-30       Impact factor: 4.411

3.  Kami-shoyo-san improves ASD-like behaviors caused by decreasing allopregnanolone biosynthesis in an SKF mouse model of autism.

Authors:  Qing-Yun Guo; Ken Ebihara; Takafumi Shimodaira; Hironori Fujiwara; Kazufumi Toume; Dya Fita Dibwe; Suresh Awale; Ryota Araki; Takeshi Yabe; Kinzo Matsumoto
Journal:  PLoS One       Date:  2019-01-31       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.